

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE SUBOXONE (BUPRENORPHINE
HYDROCHLORIDE AND NALOXONE)
ANTITRUST LITIGATION**

THIS DOCUMENT RELATES TO:,

Wisconsin, et al. v. Indivior Inc. et al.
Case No. 16-cv-5073

STATE OF WISCONSIN

By Attorney General Brad D. Schimel, et al.

Plaintiffs,

v.

**INDIVIOR INC. f/k/a RECKITT BENCKISER
PHARMACEUTICALS, INC., et al.**

Defendants.

**MDL NO. 2445
13-MD-2445**

CIV. A. NO. 16-5073

ORDER

AND NOW, this 19th day of October, 2022, upon consideration of the Motion for Summary Judgment by Defendant Aquestive Therapeutics, Inc. (“Aquestive”) (MDL No. 13-2445, Doc. Nos. 702, 704; Civ. A. No. 16-5073, Doc No. 452), the Response by Plaintiffs State of Wisconsin, *et al.* (“States”) (MDL No. 13-2445, Doc. Nos. 726, 729; Civ. A. No. 16-5073, Doc Nos. 460, 466), Aquestive’s Reply (MDL No. 13-2445, Doc. Nos. 744, 750; Civ. A. No. 16-5073, Doc No. 472), and the States’ Sur-reply (MDL No. 13-2445, Doc. Nos. 757, 758; Civ. A. No. 16-5073, Doc Nos. 477, 478), and following oral argument on the Motion, it is hereby **ORDERED** that the Motion is **GRANTED**.

JUDGMENT IS ENTERED in favor of Defendant Aquestive Therapeutics, Inc. and against Plaintiff States on all claims against Aquestive.

BY THE COURT:

/s/ Mitchell S. Goldberg
MITCHELL S. GOLDBERG, J.